GET DAILY SIGNALSGuardant Health (GH) Q3 2026: 36% Revenue Jump but Shares Drop -12% on Raised Cash Burn
Key Takeaways
- Guardant Health reported third-quarter 2026 revenue of $361 million, up 36% year over year and above the consensus estimate of roughly $351 million.
- Adjusted (non-GAAP) net loss narrowed to $0.29 per share, better than the consensus estimate of about $0.31 per share.
- Oncology revenue grew 25% to $231.3 million, while Shield screening revenue surged 180% to $67.6 million on test volume that more than tripled.
- Full-year 2026 revenue guidance was raised to $1.36–$1.37 billion, but free cash flow burn guidance was also increased, disappointing investors.
- Shares fell by a double-digit percentage in after-hours trading, reflecting concerns about cash burn despite strong top-line growth.
Earnings Context and Why It Matters
Guardant Health stands out as a precision oncology company focused on blood-based tests for cancer screening, therapy selection, and monitoring. Its third-quarter 2026 results carried extra significance, providing an update on two key growth areas: the Shield blood test for colorectal cancer screening and the Guardant360 oncology business. Following a strong second quarter, attention centered on whether Shield’s commercial progress could continue with expanding payer coverage and how much cash investment would be needed to support that expansion. The report arrived amid volatility in blood-testing stocks, so updates to guidance and the free cash flow path stood out as much as the revenue beat itself. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Reported Results
For the third quarter ended September 30, 2026, Guardant Health posted revenue of $361 million. That marked a 36% rise from $265 million a year earlier and topped the consensus estimate of roughly $351 million. The adjusted (non-GAAP) net loss came in at $0.29 per share, narrower than the expected $0.31 per share and an improvement from the $0.39 adjusted loss in the prior-year quarter. On a GAAP basis, the net loss per share was $0.93.
Growth appeared across segments. Oncology revenue climbed 25% to $231.3 million, supported by a 58% jump in test volume to 117,000 tests. Screening revenue rose 180% to $67.6 million as Shield test volume more than tripled to 83,000 tests. Biopharma & Data revenue increased 8% to $59 million. The company lifted its full-year 2026 revenue outlook to $1.36–$1.37 billion from the prior $1.34–$1.36 billion range, while also raising its free cash flow burn guidance to $205–$220 million.
Market Reaction and Investor Sentiment
Even with the top- and bottom-line beats, shares of GH declined roughly 12% to 14% in after-hours trading. The stock had already slipped about 9% during the regular session amid broader weakness in the blood-testing sector. Investors seemed to zero in on the higher free cash flow burn guidance, which pointed to greater investment needs for scaling the Shield screening business than earlier forecasts had suggested. This reaction highlighted a common dynamic for high-growth diagnostics companies: solid revenue growth alone may not satisfy the market when spending levels rise as well.
Forward Outlook and Key Factors to Monitor
Looking ahead, several elements tied to Shield’s commercial progress and the oncology portfolio will likely draw attention. Management noted continued payer coverage momentum, with new policies expected to expand Shield access to roughly 100 million covered lives—more than 80% of the eligible U.S. screening population—entering 2027. The speed at which this coverage converts into sustained test volume and stable pricing will remain a key focus.
Regulatory and reimbursement steps also stand out. Guardant Health secured FDA approval for Guardant360 CDx for longitudinal ESR1 testing in breast cancer and is pursuing ADLT designation for Guardant360 Liquid CDx in the first half of 2027, which could aid higher reimbursement. Advances with the Reveal minimal residual disease franchise and the planned launch of the higher-sensitivity Reveal Ultra test represent further potential catalysts.
Cost discipline will stay in view. The updated cash burn outlook, alongside ongoing investment in screening infrastructure, means tracking whether Shield’s cost per test keeps declining and whether the company remains on path toward its longer-term cash-flow breakeven goal. These factors, beyond headline revenue growth, are likely to influence sentiment in coming quarters.
Using AI Tools for Deeper Analysis
In my own review of earnings like this one, I often turn to Tickeron’s AI Screener to quickly compare GH against peers in the diagnostics space. The tool lets me filter by technical patterns, fundamentals, and performance metrics in one place, which helps surface context on how the company stacks up without spending hours on manual checks. It has become a regular part of how I prepare for earnings discussions and monitor sector shifts.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
GH's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for GH turned positive on October 26, 2026. Looking at past instances where GH's MACD turned positive, the stock continued to rise in 38 of 43 cases over the following month. The odds of a continued upward trend are 88%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 23, 2026. You may want to consider a long position or call options on GH as a result. In 65 of 80 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 81%.
The 10-day moving average for GH crossed bullishly above the 50-day moving average on October 29, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 73%.
Following a +4.07% 3-day Advance, the price is estimated to grow further. Considering data from situations where GH advanced for three days, in 244 of 295 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
The Aroon Indicator entered an Uptrend today. In 185 of 210 cases where GH Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 88%.
Bearish Trend Analysis
The 10-day RSI Indicator for GH moved out of overbought territory on October 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 31 similar instances where the indicator moved out of overbought territory. In 23 of the 31 cases, the stock moved lower in the following days. This puts the odds of a move lower at 74%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 49 of 65 cases where GH's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 75%.
GH moved below its 50-day moving average on November 04, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
GH broke above its upper Bollinger Band on October 26, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 18 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-92.386) is normal, around the industry mean (66.911). P/E Ratio (-43.712) is within average values for comparable stocks, (2.514). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (19.120) is also within normal values, averaging (9.775).
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. GH’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 64 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 85, placing this stock slightly better than average.
The Tickeron PE Growth Rating for this company is 66 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of diagnostic technologies to improve cancer management
Industry MedicalSpecialties
Advertisement